Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.
Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the present lack of a biomarker for targeted therapies in patients with ER-positive, HER2-negative metastatic breast cancer. Seidman says currently there is not a HER2 histochemical test for gene amplification or signatures to best select patients for either CDK46 or MTOR inhibitor, as well for PI3 kinase inhibition.
Seidman says these biomarkers could help in selecting patients for the best targeted therapies available for their particular cancers.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More